Healthcare / BiotechnologyStockholm
$0.56
-0.05 (-7.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-56.8M · quality 51.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$185M
P/E
1.9x
↓EV/EBITDA
N/A
•ROE
-226.5%
↓Gross Margin
20.3%
↓Debt/Equity
0.95
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+138.6%
FCF CAGR
—
FCF margin
-193.7%
FCF / Net income
0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $21.1M · net income $-51.3M · FCF $-40.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $21.1M | $21.1M | $14.5M | $1.4M | $1.6M |
| Net Income | $-51.3M | $-51.3M | $-65.6M | $-75.2M | $-55.2M |
| EBITDA | $-34.9M | $-34.9M | $-45.2M | $-54.8M | $-38.4M |
| EPS | -0.57 | -0.57 | -1.31 | -2.06 | -1.74 |
| Gross Margin | 20.3% | 20.3% | 29.5% | -5.3% | 208.0% |
| Operating Margin | -233.7% | -233.7% | -329.6% | -3812.4% | -3224.2% |
| Net Margin | -242.8% | -242.8% | -451.4% | -5208.4% | -3551.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.95 | 0.95 | 0.69 | -0.35 | 0.06 |
| Current Ratio | 1.15 | 1.15 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-40.9M | $-40.9M | $-81.5M | $-56.8M | $-53.8M |
| Returns | |||||
| ROE | -226.5% | -226.5% | -88.6% | 3959.8% | -75.5% |
| Valuation | |||||
| P/E | 1.94 | 1.94 | — | — | — |
| P/B | 2.22 | 2.22 | 1.24 | — | 4.23 |
| Growth & Yield | |||||
| Revenue Growth | 45.3% | 45.3% | 907.5% | -7.2% | — |
| EPS Growth | 56.1% | 56.1% | 36.5% | -18.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-43.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.31 → -0.57
Residual
-43.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.